Tuberculosis Patents (Class 514/924)
-
Patent number: 11535703Abstract: The present disclosure relates to synthesis of porous polymer networks and applications of such materials. The present disclosure relates to a method of fabricating of a porous polymer network comprising: (a) providing: (i) a first reactant comprising a plurality of compounds comprising at least one acetyl group, said plurality of compounds comprising at least one compound type, and (ii) a second reactant comprising an alkylsulfonic acid, and (b) creating a solution of said reactants, (c) casting said solution in a form, and (d) treating said solution under such conditions so as to produce a porous polymer network.Type: GrantFiled: January 28, 2021Date of Patent: December 27, 2022Assignee: THE TEXAS A&M UNIVERSITY SYSTEMInventors: Lei Fang, Zi-Hao Guo, Chenxu Wang, Qiang Zhang, Hong-Cai Zhou
-
Patent number: 8846607Abstract: Formulations have been developed to treat or reduce the spread of respiratory infections, especially chronic or drug resistant infections, particularly tuberculosis (TB), severe acute respiratory syndrome (SARS), meningococcal meningitis, Respiratory syncytial virus (RSV), influenza, and small pox. Formulations include a drug or vaccine in the form of a microparticle, nanoparticle, or aggregate of nanoparticles, and, optionally, a carrier, which can be delivered by inhalation. Giving the drugs via an inhaler sidesteps the problems associated with oral or injectable drugs by bypassing the stomach and liver, and delivering the medication directly into the lungs. In one embodiment, the particle containing the agent is a large porous aerosol particle (LPPs). In another embodiment, the particles are nanoparticles, which can be administered as porous nanoparticle aggregates with micron diameters that disperse into nanoparticles following administration.Type: GrantFiled: October 19, 2005Date of Patent: September 30, 2014Assignee: President and Fellows of Harvard CollegeInventors: David A. Edwards, Jennifer Fiegel, Jean Sung
-
Patent number: 8841286Abstract: A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a concentrated formulation of aztreonam lysinate delivered as an aerosol or dry powder formulation.Type: GrantFiled: September 26, 2011Date of Patent: September 23, 2014Assignee: Gilead Sciences, Inc.Inventor: Alan Bruce Montgomery
-
Patent number: 8012508Abstract: The present invention relates to method of targeting therapeutic agents for treating lung diseases.Type: GrantFiled: January 15, 2008Date of Patent: September 6, 2011Assignee: Abbott Cardiovascular Systems Inc.Inventor: Florian N. Ludwig
-
Patent number: 7989004Abstract: The present invention relates to enhancement of anti-tubercular activity of active fraction isolated from Salicornia brachiata. The invention also discloses the non-toxic nature of the fraction and positively identifies Sucrose as its main constituent. Pure Sucrose is shown to have no anti-tubercular activity indicating thereby that activity of the fraction resides in one or more of the minor constituents. The minor constituents are shown to be relatively low molecular weight entities and a chromatographic technique is disclosed for separating them from the bulk sucrose to probe their activities and structures in detail, as also the possibility of their synthesis if the leads thrown up are novel.Type: GrantFiled: January 23, 2006Date of Patent: August 2, 2011Assignee: Council of Scientific and Industrial ResearchInventors: Meena Rajnikant Rathod, Bhupendra Dhanvantrai Shethia, Jayant Batukral Pandya, Pushpito Kumar Ghosh, Prakash Jagivanbhal Dodia, Brahm S. Srivastava, Ranjana Srivastava, Anil Srivastava, Vinita Chaturvedi, Mariappanadar Vairamani
-
Patent number: 7651705Abstract: Provided herein are synergistic herbal compositions for the treatment of gastric ulcer, said composition essentially comprising powdered plant parts of Asparagus racemosus, Glycyrrhiza glabra, Sesamum indicum, Musa sapientum and Trachyspermum roxburghianum and optionally, powdered plant parts of Cyclea peltata, Embelia ribes, Coriandrum sativum Ferulaasafetida, Aloe barbadensis and Evolvulus aisinodes along with one or more pharmaceutically acceptable additives/carriers, processes for preparing such compositions and methods for treating gastric ulcers using such compositions.Type: GrantFiled: October 28, 2003Date of Patent: January 26, 2010Assignee: Council of Scientific & Industrial ResearchInventors: Janaswamy Madhusudana Rao, Upparapalli Sampathkumar, Boggavarapu Subrahmanya Sastry, Jhillu Singh Yadav, Kondapuram Vijaya Raghavan, Gautam Palit, Dwaraka Nath Bhalla, Deepak Rai, Panniyampally Madhavankutty Varier, Trikovil Sankaran Muraleedharan, Kollath Muraleedharan
-
Patent number: 7524517Abstract: This invention relates generally to a method of increasing cytosolic Ca2+ levels in mammalian cells comprising contacting P2X receptor Ca2+ entry channels or any and all other Ca2+ entry channels or mechanisms on the cell with an effective amount of a small molecule, and a composition comprising the small molecule in a delivery system. The invention has broad applicability in the pharmaceutical industry as a method of treating airway diseases (such as cystic fibrosis and asthma), ailments of the lung and airways (such as those caused by common cold pathogens or allergens in allergy), kidney diseases and renal hypertensive disorders (such as polycystic kidney disease and salt-sensitive hypertension syndromes), and endocrine disorders (such as diabetes).Type: GrantFiled: January 20, 2004Date of Patent: April 28, 2009Assignee: UAB Research FoundationInventors: Erik Schwiebert, Akos Zsembery
-
Patent number: 7442393Abstract: The present invention relates to extracts of Salicornia species. The present invention particularly relates to extracts of Salicornia species which show antitubercular activity. The present invention also relates to a process for the preparation of novel extracts of Salicornia species with antitubercular activity and also to the use thereof for the treatment of tuberculosis.Type: GrantFiled: June 26, 2007Date of Patent: October 28, 2008Assignee: Council of Scientific and Industrial ResearchInventors: Meena Rajnika Rathod, Bhupendra D. Shethia, Jayant B. Pandya, Pushpito K. Ghosh, Prakash J. Dodia, Brahm S. Srivastava, Ranjana Srivastava, Anil Srivastava, Vinita Chaturvedi
-
Patent number: 7214364Abstract: A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a concentrated formulation of aztreonam lysinate delivered as an aerosol or dry powder formulation.Type: GrantFiled: July 3, 2003Date of Patent: May 8, 2007Assignee: Corus Pharma, Inc.Inventor: Alan Bruce Montgomery
-
Patent number: 7150888Abstract: Strong vapors from eucalyptus oil and tea tree oil are inhaled periodically to prevent respiratory system diseases including colds, flus, pneumonia, tuberculosis, and opportunistic infections in individuals having cystic fibrosis. Apparatus for the periodic inhalation of strong vapors from eucalyptus oil and tea tree oil are provided.Type: GrantFiled: September 9, 2002Date of Patent: December 19, 2006Assignee: Inhalation, Inc.Inventors: William Banning Vail, III, Marilyn L. Vail
-
Patent number: 7135195Abstract: We disclose a colorless composition comprising silver particles and water, wherein said particles comprise an interior of elemental silver and an exterior of ionic silver oxide, wherein the silver particles are present in the water at a level of about 5–40 ppm, and wherein the composition manifests significant antimicrobial properties. Methods of use of the composition are described.Type: GrantFiled: August 15, 2003Date of Patent: November 14, 2006Assignee: American Silver, LLCInventors: Robert J. Holladay, Herbert Christensen, William D. Moeller
-
Patent number: 7122577Abstract: A composition including a purified lipid cell-wall component or analog or derivative thereof and a suitable pharmaceutical carrier, medium, excipient or adjuvant is described. The composition is useful in prophylactic and therapeutic methods of treating a microbial infection in a subject, typically a mycobacterial infection such as tuberculosis, and immune disorders, inflammatory conditions and allergies in a subject, typically autoimmune diseases. It is also useful in diagnostic methods. The purified lipid cell-wall component is typically a purified mycolic acid or a mixture of purified mycolic acids from a bacterium which produces mycolic acids. The bacterium is from Mycobacterium, Corynebacterium, Nicardia or Rhodococcus.Type: GrantFiled: October 25, 2000Date of Patent: October 17, 2006Assignee: Adcock Ingram LimitedInventors: Jan Adrianus Verschoor, Anne Lenaerts, Elzbieta Johannsen
-
Patent number: 6989157Abstract: Dry powders of metal-containing compounds are disclosed. Methods of preparing and using the dry powders, particularly in the treatment of a subject having a condition, are also disclosed. The metal-containing material can be, for example, an antimicrobial material, an antibacterial material, an anti-inflammatory material, an anti-fungal material, an anti-viral material, an anti-cancer material, a pro-apoptosis material, and/or an MMP modulating material. In certain embodiments, the metal-containing material is an atomically disordered, silver-containing material.Type: GrantFiled: October 22, 2002Date of Patent: January 24, 2006Assignee: Nucryst Pharmaceuticals Corp.Inventors: Scott H. Gillis, Paul Schechter, Robert E. Burrell
-
Patent number: 6951961Abstract: Methods and compositions for treating disease caused by microorganisms, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis.Type: GrantFiled: May 17, 2002Date of Patent: October 4, 2005Inventors: Marina Nikolaevna Protopopova, Richard Edward Lee, Richard Allan Slayden, Clifton E. Barry, III
-
Patent number: 6866871Abstract: Dry powders of metal-containing compounds are disclosed. Methods of preparing and using the dry powders, particularly in the treatment of a subject having a condition, are also disclosed. The metal-containing material can be, for example, an antimicrobial material, an antibacterial material, an anti-inflammatory material, an anti-fungal material, an anti-viral material, an anti-cancer material, a pro-apoptosis material, and/or an MMP modulating material. In certain embodiments, the metal-containing material is an atomically disordered, silver-containing material.Type: GrantFiled: October 22, 2002Date of Patent: March 15, 2005Assignee: Nucryst Pharmaceuticals Corp.Inventors: Scott H. Gillis, Paul Schechter, Robert E. Burrell
-
Patent number: 6852484Abstract: The present inventors have discovered that Asparagine Synthase is essential for fungal pathogenicity. Specifically, the inhibition of Asparagine Synthase gene expression in fungi results in no signs of successful infection or lesions. Thus, Asparagine Synthase can be used as a target for the identification of antibiotics, preferably antifungals. Accordingly, the present invention provides methods for the identification of compounds that inhibit Asparagine Synthase expression or activity. The methods of the invention are useful for the identification of antibiotics, preferably antifungals.Type: GrantFiled: December 10, 2001Date of Patent: February 8, 2005Assignee: Icoria, Inc.Inventors: Sze-Chung Lo, Maria Victoria Montenegro-Chamorro, Sheryl Frank, Blaise Darveaux, Sanjoy Mahanty, Ryan Heiniger, Amy Skalchunes, Huaqin Pan, Rex Tarper, Jeffrey Shuster, Matthew M. Tanzer, Lisbeth Hamer, Kiichi Adachi, Todd M. DeZwaan
-
Patent number: 6835755Abstract: Naphthoquinone derivatives of Formula (1): wherein R, represents an OH group, methyl ether, ethyl ether or a similar ether, R1 represents a methyl, ethyl or similar aliphatic hydrocarbon derivative: R2 and R3 each independently represent hydrogen or a group selected from: (A), (B), or (C) wherein R5 represents an PH group, methyl ether, ethyl ether or a similar ether and R6 represents a methyl, ethyl or similar aliphatic hydrocarbon derivative: R4 represents hydrogen or a group selected from: (D), (E) or (F) wherein R7 represents an OH group, methyl ether, ethyl ether or a similar ether and R8 represents a methyl, ethyl or similar aliphatic hydrocarbon derivative: or pharmaceutically acceptable salts thereof, are useful for the treatment and/or control of a tuberculosis in a patient caused by Mycobacterium tuberculosis.Type: GrantFiled: March 19, 2002Date of Patent: December 28, 2004Assignees: University of Pretoria, South African Medical Research CouncilInventors: Jacobus Johannes Marion Meyer, Namrita Lall
-
Patent number: 6733963Abstract: The present inventors have discovered that 3-Isopropylmalate dehydratase is essential for fungal pathogenicity. Specifically, the inhibition of 3-Isopropylmalate dehydratase gene expression in fungi results in no signs of successful infection or lesions. Thus, 3-Isopropylmalate dehydratase can be used as a target for the identification of antibiotics, preferably antifungals. Accordingly, the present invention provides methods for the identification of compounds that inhibit 3-Isopropylmalate dehydratase expression or activity. The methods of the invention are useful for the identification of antibiotics, preferably antifungals.Type: GrantFiled: December 6, 2001Date of Patent: May 11, 2004Assignee: Paradigm Genetics, Inc.Inventors: Lisbeth Hamer, Kiichi Adachi, Todd DeZwaan, Sze-Chung Lo, Maria Victoria Montenegro-Chamorro, Sheryl Frank, Blaise Darveaux, Sanjoy Mahanty, Ryan Heiniger, Amy Skalchunes, Huaqin Pan, Rex Tarpey, Jeffrey Shuster, Matthew M. Tanzer
-
Patent number: 6566354Abstract: A method for treatment of bacterial infections with rifalazil administered once-weekly or twice-weekly. A method for treatment of tuberculosis caused by Mycobacterium tuberculosis, infections caused by Mycobacterium avium complex, infections caused by Chlamydia pneumoniae and infections caused by Helicobacter pylori by administering to a patient suffering from the bacterial infection 1-100 mg of rifalazil once or twice a week. In this dose regimen, the treatment is fast, efficacious and eliminates undesirable secondary symptoms observed with daily doses of 1-50 mg of rifalazil.Type: GrantFiled: October 5, 2001Date of Patent: May 20, 2003Assignee: Kaneka CorporationInventors: Lynn M. Rose, David J. Porubek, Alan B. Montgomery
-
Patent number: 6517845Abstract: The invention relates to Mycobacterium tuberculosis superoxide dismutase antibodies, methods of using them for detection of M. tuberculosis, methods of testing for an inhibitor of an M. tuberculosis superoxide dismutase, and methods of detecting tuberculosis infection.Type: GrantFiled: November 12, 1999Date of Patent: February 11, 2003Assignee: Yung Shin Pharmaceutical Ind. Co., Ltd.Inventors: Fang-Jen S. Lee, Chung-Hsiun H. Wu
-
Patent number: 6514541Abstract: A formulation useful in the treatment of drug resistant bacterial infections comprising an effective amount of thymol obtained from the plant Trachyspermum ammi, mint oil containing an appropriate amount of monoterpenes obtained from a hybrid of Mentha spicata and Mentha arvensis, and conventional additives. A method for producing the formulation by mixing the above ingredients and a method for the treatment of drug resistance in a patient by administration of a therapeutically effective amount of the formulation.Type: GrantFiled: March 28, 2000Date of Patent: February 4, 2003Assignee: Council of Scientific and Industrial ResearchInventors: Suman Preet Singh Khanuja, Suchi Srivastava, Ajit Kumar Shasney, Mahendra Pandurang Darokar, Tiruppadiripuliyur Ranganathan Santha Kumar, Krishna Kumar Agarwal, Ateeque Ahmed, Nirmal Kumar Patra, Prachi Sinha, Sunita Dhawan, Dharmendra Saikia, Sushil Kumar
-
Patent number: 6433013Abstract: A composition comprising a purified lipid cell-wall component or analog or derivative thereof and a suitable pharmaceutical carrier, medium, excipient or adjuvant is described. The composition is useful in prophylactic and therapeutic methods of treating a microbial infection in a subject, typically a mycobacterial infection such as tuberculosis, and immune disorders, inflammatory conditions and allergies in a subject, typically autoimmune diseases. It is also useful in diagnostic methods. The purified lipid cell-wall component is typically a purified mycolic acid or a mixture of purified mycolic acids from a bacterium which produces mycolic acids. The bacterium is from Mycobacterium, Corynebacterium, Nocardia or Rhodococcus.Type: GrantFiled: September 2, 1999Date of Patent: August 13, 2002Assignee: Adcock Ingram LimitedInventors: Jan Adrianus Verschoor, Anne Lenaerts, Elzbieta Johannsen
-
Patent number: 6403623Abstract: Method for treating tuberculosis with 2-(2-substituted-phenyl)-2-oxazolines and related 5-membered heterocycles represented by the formula Y1 is e.g. an ester or amide forming group, and X is O, S, or NH; and pharmaceutically acceptable formulations useful therein are provided. A preferred method comprises administering (S)-benzyl2-[2-(benzyloxy)phenyl]-2-oxazoline-4-carboxylate in a suitable formulation. The compounds of the above formula are prepared by known methods, e.g. the oxazolines are obtained by coupling a substituted benzoic acid with a serine ester or threonine ester and cyclizing the coupled product.Type: GrantFiled: May 25, 2000Date of Patent: June 11, 2002Assignee: Unuversity of Notre Dame du LacInventors: Marvin J. Miller, Jingdan Hu
-
Patent number: 6316433Abstract: A method for treatment of bacterial infections with rifalazil administered once-weekly or twice-weekly. A method for treatment of tuberculosis caused by Mycobacterium tuberculosis, infections caused by Mycobacterium avium complex, infections caused by Chlamydia pneumoniae and infections caused by Helicobacter pylori by administering to a patient suffering from the bacterial infection 1-100 mg of rifalazil once or twice a week. In this dose regimen, the treatment is fast, efficacious and eliminates undesirable secondary symptoms observed with daily doses of 1-50 mg of rifalazil.Type: GrantFiled: December 15, 1999Date of Patent: November 13, 2001Assignee: Kaneka CorporationInventors: Lynn M. Rose, David J. Porubek, Alan B. Montgomery
-
Patent number: 6284255Abstract: The present invention provides polypeptides comprising an immunogenic portion of a M. vaccae soluble protein and DNA molecules encoding such polypeptides, together with methods for their use in the diagnosis and treatment of mycobacterial infection. Methods for enhancing the immune response to an antigen including administration of M. vaccae culture filtrate or delipidated M. vaccae cells are also provided.Type: GrantFiled: August 29, 1996Date of Patent: September 4, 2001Assignee: Genesis Research & Development Corporation LimitedInventors: Paul Tan, Jun Hiyama, Elizabeth Visser, Linda Scott
-
Patent number: 6238661Abstract: Compositions and methods for the prophylactic and therapeutic treatment of bacterial infections are disclosed which comprise administering to an individual an effective amount of a composition comprising an effective amount of lytic enzyme and a carrier for delivering the lytic enzyme. This method and composition can be used for the treatment of upper respiratory infections, skin infections, wounds, burns, vaginal infections, eye infections, intestinal disorders and dental problems.Type: GrantFiled: April 18, 2000Date of Patent: May 29, 2001Assignee: New Horizons Diagnostics Corp.Inventors: Vincent Fischetti, Lawrence Loomis
-
Patent number: 6214789Abstract: The present invention relates to methods for treating a subject suffering from infection with Mycobacteria, such as M. leprae or M. tuberculosis comprising administering to the subject a composition comprising a bactericidal/permeability-inducing (BPI) protein product alone or in combination with administration of an anti-Mycobacterial antibiotic.Type: GrantFiled: April 1, 1996Date of Patent: April 10, 2001Assignee: Xoma CorporationInventor: Lewis H. Lambert, Jr.
-
Patent number: 6203822Abstract: This invention relates to the use of gallium-containing compounds, to inhibit intracellular pathogens including pathogens that are members of the genus Mycobacteria, Legionella, Histoplasma, and Leishmania and to organisms causing chronic pulmonary infection such P. aeruginosa.Type: GrantFiled: September 3, 1996Date of Patent: March 20, 2001Assignee: University of Iowa Research FoundationInventors: Larry S. Schlesinger, Bradley E. Britigan
-
Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
Patent number: 6083922Abstract: A method for treatment, prevention and containment of acute and chronic tuberculosis using a preservative-free concentrated tobramycin aerosol formulation delivering tobramycin to the lung endobronchial space including alveoli in an aerosol having mass medium average diameter predominantly between 1 to 5.mu.. The method comprises administration of tobramycin in concentration one to ten thousand times higher than the minimal inhibitory concentration of Mycobacterium tuberculosis. A method for containment of and decreasing infectivity periods of tuberculosis patients to shorter periods of time.Type: GrantFiled: April 2, 1997Date of Patent: July 4, 2000Assignee: Pathogenesis, Corp.Inventor: Alan Bruce Montgomery -
Patent number: 5998420Abstract: The present invention is directed to a method for treating tuberculosis in a mammal which comprises administering to the mammal a therapeutically effective amount of an inhibitor compound that inhibits an enzyme in the branched chain amino acid biosynthetic pathway in Mycobacterium tuberculosis.Type: GrantFiled: April 8, 1996Date of Patent: December 7, 1999Assignee: University of Medicine & Dentistry of New JerseyInventor: Jerry Grandoni
-
Patent number: 5837732Abstract: The present invention provides a compound having the structure: ##STR1## wherein R is a branched or unbranched C1-C30 alkyl, alkenyl or alkynl; or a branched or unbranched C1-C30 alkyl, alkenyl or alkynl substituted with S, O, N, P, SO.sub.2, F, Cl, Br, or I, wherein S, O, N, P, or SO.sub.2 replaces at least one --CH.sub.2 --, and F, Cl, Br, or I replaces at least one H. The present invention also provides a pharmaceutical composition comprising the compound above, as well as a method for treating a mycobacterial disease or infection in a subject in need of such treatment by administering to the subject an effective amount of the compound above.Type: GrantFiled: December 13, 1996Date of Patent: November 17, 1998Assignees: Albert Einstein College of Medicine of Yeshiva University, The Research Foundation of the City University of New YorkInventors: James Sacchettini, John Blanchard, William R. Jacobs, Robert Bittman
-
Patent number: 5798391Abstract: Solution administrable by intravascular injection in a human or an animal which comprises an effective amount up to 0.23% by weight of a benzalkonium fluoride having the formula: ##STR1## where R is an alkyl radical which may vary between C.sub.8 H.sub.17 and C.sub.18 H.sub.37, dissolved in an excipient injectable intravascularly. Preferably R is between C.sub.12 H.sub.25 and C.sub.14 H.sub.29, and more preferably C.sub.14 H.sub.29. The solution can be packaged in 10 ml ampoules, containing about 21 mg of benzalkonium fluoride, the benzalkonium fluoride being dissolved in a physiological solvent. The solution also contains at least one metallic derivative of fluorine, preferably lithium fluoride.Type: GrantFiled: October 22, 1996Date of Patent: August 25, 1998Assignee: Aromafarm LimitedInventors: Pierre Lagny, Pierre Bourbon
-
Patent number: 5683675Abstract: A method of facilitating the clearance of retained pulmonary secretions in a subject using lantibiotics is disclosed. The method comprises administering to the lungs of the subject an effective amount of a lantibiotic. The lantibiotic is preferably administered by topically applying it to the respiratory epithelia, such as by generating an aerosol thereof which is then inhaled by the subject. A preferred lantibiotic for carrying out the present invention is duramycin. The method may be used in treating disorders such as cystic fibrosis, chronic bronchitis, and asthma. Also disclosed is a method of combatting tuberculosis comprising administering a lantibiotic to a subject in need of such treatment.Type: GrantFiled: May 2, 1995Date of Patent: November 4, 1997Assignee: Molichem Medicines, Inc.Inventors: Luis Miguel Molina y Vedia, Monroe Jackson Stutts, Richard C. Boucher, Jr., David C. Henke
-
Patent number: 5648392Abstract: The present invention provides a compound having the structure: ##STR1## wherein R is a branched or unbranched C1-C30 alkyl or alkenyl; or a branched or unbranched C1-C30 alkyl or alkenyl substituted with S, O, N, P, SO.sub.2, F, C1, Br, or I, wherein S, O, N, P, or SO.sub.2 replaces at least one --CH.sub.2 --, and F, Cl, Br, or I replaces at least one H. The present invention also provides a pharmaceutical composition comprising the compound above, as well as a method for treating a mycobacterial disease or infection in a subject in need of such treatment by administering to the subject an effective amount of the compound above.Type: GrantFiled: February 7, 1995Date of Patent: July 15, 1997Assignee: Albert Einstein College of Medicine of Yeshiva University, a Division of Yeshiva UniversityInventors: James Sacchettini, John Blanchard, William R. Jacobs
-
Patent number: 5624912Abstract: Oligonucleotides, polynucleotides and derivatives thereof, such as defibrotide, are agents of genetic modulation at the levels of transcription, translation, secondary messengers and cellular signal transduction systems. Such agents can be used to treat HIV infection. Preferably, treatment involves modifying the dose of such agents in response to observed fluctuations (e.g., increase, decrease, appearance, disappearance) in normal, disease and repair markers.Type: GrantFiled: January 24, 1994Date of Patent: April 29, 1997Inventors: Arsinur Burcoglu, Marc Wagner
-
Patent number: 5565473Abstract: Compounds having the formula I: ##STR1## are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.Type: GrantFiled: February 23, 1995Date of Patent: October 15, 1996Assignee: Merck Frosst Canada, Inc.Inventors: Michel L. Belley, Serge Leger, Marc Labelle, Patrick Roy, Yi B. Xiang, Daniel Guay
-
Patent number: 5529778Abstract: An ayurvedic composition for prophylaxis and treatment of AIDS, flu, TB, and other immuno-deficiency conditions, and for liver diseases such as hepatitis and sclerosis, includes prescribed doses of extracts or isolates of two multi-component drugs in selected proportions. The first multi-component drug, LIVZON, consists of Phyllanthus niruri (292-310 mg.), Tinospora cordifolia (190-210 mg.), Phyllanthus emblica (90-110 mg.), Terminalia belerica (90-110 mg.), and Terminalia chebula (290-310 mg.); and the second multi-component drug, IMMINEX, consists of Holarrhena antidysenterica (40-60 mg.), Picrorhiza kurrooa (40-60 mg.), and Swertia chirata (15-35 mg.). The beneficial composition may be administered in the form of aqueous extracts, hard gelatin capsules, or mixed with syrup. The process of making the composition requires the basic ingredients to be cleaned, washed, dried and separated from all extraneous matter, after which they are powdered and extracts obtained therefrom with distilled water.Type: GrantFiled: September 13, 1994Date of Patent: June 25, 1996Inventor: Surendra Rohatgi
-
Patent number: 5439891Abstract: A new pharmaceutical composition for the treatment of tuberculosis and leprosy, said composition comprising piperine in combination with known antituberculosis or antileprosy drugs or the mixtures thereof.Type: GrantFiled: October 29, 1993Date of Patent: August 8, 1995Inventors: Randhir S. Kapil, Usha Zutshi, Kasturi L. Bedi, Gurbax Singh, Ramesh K. Johri, Santosh K. Dhar, Jawahar L. Kaul, Subhash C. Sharma, Gurcharan S. Pahwa, Naveen Kapoor, Ashok K. Tickoo, Manoj K. Tickoo, Uma Kaul, Surjeet Singh, Ram K. Zutshi, Rajinder Singh
-
Patent number: 5162361Abstract: The present invention relates to a method of treating diseases associated with elevated levels of interleukin 1 (IL-1) including inflammatory diseases such as arthritis, skin hypersensitivity and endotoxemia. More specifically, the invention relates to a method for the treatment of such diseases in warm-blooded animals, such as humans, which comprises the administration of a therapeutically effective amount of an aromatic diamidine, sufficient to inhibit IL-1 release from IL-1 producing cells. The aromatic diamidine can also be used to block interleukin 6 (IL-6) and tumor necrosis factor from cells producing these cytokines.Type: GrantFiled: April 10, 1990Date of Patent: November 10, 1992Assignee: The United States of America as represented by the Secretary, Department of Health and Human ServicesInventors: Gary J. Rosenthal, Yasuhida Kouchi, Emanuela Corsini, Benny Blaylock, Christine Comment, Michael Luster, William Craig, Michael Taylor
-
Patent number: 5089475Abstract: The invention relates to a method of treating pulmonary dysfunction in a mammal comprising administration of growth hormone to said mammal. In one embodiment wherein the pulmonary dysfunction results in ventilator dependency, the use of the method of this invention promotes the withdrawal of mechanical ventilatory support.Type: GrantFiled: February 7, 1989Date of Patent: February 18, 1992Assignee: Brigham and Women's HospitalInventor: Douglas W. Wilmore
-
Patent number: 4962111Abstract: Pyrazinoic esters have been prepared. Compounds of this group are effective against mycobacteria including Mycobacteria tuberculosis, pyrazinamide-resistant Mycobacteria tuberculosis, Mycobacteria bovis and Mycobacteria kansasii.Type: GrantFiled: June 8, 1989Date of Patent: October 9, 1990Assignee: The Research Foundation of State University of New YorkInventors: John T. Welch, Michael H. Cynamon
-
Patent number: 4851437Abstract: Various tung oil or tung oil fatty acid compositions and use thereof for treating at least some symptoms of body defense deficiencies in patients having said symptoms.Type: GrantFiled: August 12, 1986Date of Patent: July 25, 1989Assignee: Elena AvramInventor: Emanuel Revici